BACKGROUND: Little is known about the cost-effectiveness of secondary prevention after percutaneous coronary intervention (PCI). The aim of this study was to estimate the cost-effectiveness of statin therapy. METHODS: A cost-effectiveness analysis was performed using data from the Lescol Intervention Prevention Study (LIPS). In the LIPS trial, patients with normal-to-moderate hypercholesterolaemia who had undergone a first PCI were randomised to receive either fluvastatin 40 mg twice-daily plus dietary counselling or dietary counselling alone. A Markov model was used to estimate the incremental costs per quality-adjusted life year (QALY) and life year gained (LYG). Costs were based on prices and reimbursed charges, utility data were drawn from literature. Monte Carlo simulations and multivariate analysis were used to assess uncertainty. RESULTS: Routine statin treatment costs an additional €734 (SD €686) per patient over ten years compared with controls. It resulted in an additional 0.078 (0.047) QALYs or 0.082 (0.041) LYG. The incremental costs per QALY and LYG were €9312 (€14,648) and €8954 (€16,617) respectively. Anticipating a willingness to pay of €20,000 per QALY, there is a 75.1% chance that fluvastatin treatment is cost-effective. CONCLUSION:Statin therapy with fluvastatin is economically efficient with regard to reducing heart disease in the Netherlands when given routinely to all patients following PCI.
RCT Entities:
BACKGROUND: Little is known about the cost-effectiveness of secondary prevention after percutaneous coronary intervention (PCI). The aim of this study was to estimate the cost-effectiveness of statin therapy. METHODS: A cost-effectiveness analysis was performed using data from the Lescol Intervention Prevention Study (LIPS). In the LIPS trial, patients with normal-to-moderate hypercholesterolaemia who had undergone a first PCI were randomised to receive either fluvastatin 40 mg twice-daily plus dietary counselling or dietary counselling alone. A Markov model was used to estimate the incremental costs per quality-adjusted life year (QALY) and life year gained (LYG). Costs were based on prices and reimbursed charges, utility data were drawn from literature. Monte Carlo simulations and multivariate analysis were used to assess uncertainty. RESULTS: Routine statin treatment costs an additional €734 (SD €686) per patient over ten years compared with controls. It resulted in an additional 0.078 (0.047) QALYs or 0.082 (0.041) LYG. The incremental costs per QALY and LYG were €9312 (€14,648) and €8954 (€16,617) respectively. Anticipating a willingness to pay of €20,000 per QALY, there is a 75.1% chance that fluvastatin treatment is cost-effective. CONCLUSION: Statin therapy with fluvastatin is economically efficient with regard to reducing heart disease in the Netherlands when given routinely to all patients following PCI.
Authors: L A Prosser; A A Stinnett; P A Goldman; L W Williams; M G Hunink; L Goldman; M C Weinstein Journal: Ann Intern Med Date: 2000-05-16 Impact factor: 25.391
Authors: Patrick W J C Serruys; Pim de Feyter; Carlos Macaya; Norbert Kokott; Jacques Puel; Matthias Vrolix; Angelo Branzi; Marcelo C Bertolami; Graham Jackson; Bradley Strauss; Bernhard Meier Journal: JAMA Date: 2002-06-26 Impact factor: 56.272
Authors: D M Huse; M W Russell; J D Miller; D F Kraemer; R B D'Agostino; R C Ellison; S C Hartz Journal: Am J Cardiol Date: 1998-12-01 Impact factor: 2.778
Authors: P N Ruygrok; P T de Jaegere; R T van Domburg; M J van den Brand; P W Serruys; P J de Feyter Journal: J Am Coll Cardiol Date: 1996-06 Impact factor: 24.094
Authors: J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard Journal: N Engl J Med Date: 1995-11-16 Impact factor: 91.245
Authors: Ching-Yun Wei; Ruben G W Quek; Guillermo Villa; Shravanthi R Gandra; Carol A Forbes; Steve Ryder; Nigel Armstrong; Sohan Deshpande; Steven Duffy; Jos Kleijnen; Peter Lindgren Journal: Pharmacoeconomics Date: 2017-03 Impact factor: 4.981
Authors: David Gregory; Dennis J Scotti; Gregory de Lissovoy; Igor Palacios; Simon Dixon; Brijeshwar Maini; William O'Neill Journal: Am Health Drug Benefits Date: 2013-03
Authors: Oleg Borisenko; Michael Haude; Uta C Hoppe; Tomasz Siminiak; Janusz Lipiecki; Steve L Goldberg; Nawzer Mehta; Omari V Bouknight; Staffan Bjessmo; David G Reuter Journal: BMC Cardiovasc Disord Date: 2015-05-14 Impact factor: 2.298